Kenji Nakahara

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · Journal of Medicinal Chemistry · 2022 · 553 citations · Full text

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · 2022 · 56 citations · Full text

Coronavirus Disease 2019, Molecular Pharmacology, Medicinal Chemistry +15

Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2

Kazuki Fujimoto, Eriko Matsuoka, Naoya Asada et al. · Journal of Medicinal Chemistry · 2019 · 35 citations · Full text

Drug Target, Protein Assembly, Molecular Biology +17

Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization

Kenji Nakahara, Kouki Fuchino, Kazuo Komano et al. · Journal of Medicinal Chemistry · 2018 · 32 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Pre-clinical Pharmacology +20

New Perspective for Natural Products Synthesis:  Concise Synthesis of (+)-Sch 642305 by Chiral Auxiliary Multiuse Methodology

Hiromichi Fujioka, Yusuke Ohba, Kenji Nakahara et al. · Organic Letters · 2007 · 31 citations